In November 2017, the All Wales Medicines Strategy Group recommended Somavert as a third-line treatment of acromegaly in adults.

Somavert is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs didn’t normalise IGF-I concentrations or was not tolerated.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Following a second resubmission considered under the ultra-orphan process, pegvisomant (Somavert) is accepted for use within NHS Scotland.

For the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs did not normalise IGF-I concentrations or was not tolerated.

SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

In Northern Ireland, pegvisomant (Somavert) is accepted for use

For the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs did not normalise IGF-I concentrations or was not tolerated

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in Northern Ireland or a list price that is equivalent or lower